AC Immune(ACIU) Newsfilter·2024-07-31 12:30Core Viewpoint - AC Immune SA has introduced a novel class of drug candidates called morADC (Morphomer® Antibody Drug Conjugate) aimed at improving efficacy in treating neurodegenerative diseases, as presented at the AAIC 2024 conference [1][2][3] Group 1: Technology Overview - morADC technology combines proprietary brain-penetrant small molecules (Morphomers®) with monoclonal antibodies (SupraAntigen®), targeting toxic proteins in the central nervous system (CNS) [1][2] - The morADC platform allows for single or dual-targeting strategies, enhancing therapeutic efficacy by delivering combination therapy in a single agent [2][5] - Significant synergies were observed with morADC, leading to increased blood-brain barrier penetration and enhanced potency against protein aggregation compared to using antibodies or small molecules alone [1][2][5] Group 2: Clinical Implications - The morADC technology is designed to address critical targets such as Abeta, Tau, and a-synuclein, which are associated with neurodegenerative diseases [2] - Single-targeting morADC demonstrated significant anti-aggregation effects, while dual-targeting morADC showed even greater efficacy [2][5] - The technology aims to overcome challenges faced by existing treatment modalities, potentially improving clinical outcomes for patients suffering from neurodegenerative diseases [5] Group 3: Company Background - AC Immune SA is a clinical-stage biopharmaceutical company focused on precision medicine for neurodegenerative diseases, with a diverse pipeline that includes sixteen therapeutic and diagnostic programs [6] - The company has a strong history of strategic partnerships with leading pharmaceutical companies, resulting in substantial non-dilutive funding and milestone payments [6]